U.S. Venture Partners XII L.P. 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-01-27 3:05 pm Sale |
2021-12-13 | 13D | ARS Pharmaceuticals, Inc. SPRY |
U.S. Venture Partners XII L.P. | 110,120 0.300% |
-2,160,360 (-95.15%) |
Filing |
| 2020-12-14 06:05 am Purchase |
2020-12-04 | 13D | ARS Pharmaceuticals, Inc. SPRY |
U.S. Venture Partners XII L.P. | 2,270,480 6.500% |
2,270,480 (New Position) |
Filing |